ORIGINAL ARTICLE

Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas

E Thodou, G Kontogeorgos, D Theodossiou and M Pateraki

Department of Pathology, G. Gennimatas Athens General Hospital, Athens, Greece

Correspondence to:
Correspondence to:
Dr G Kontogeorgos Department of Pathology
G. Gennimatas Athens General Hospital, 154 Messogion Avenue, GR-115 27 Athens, Greece; gkonto{at}med.uoa.gr

Background: Somatostatin is a tetradecapeptide exerting inhibitory action on endocrine and exocrine cell secretion and proliferation. Somatostatin receptors (SST) are widely expressed in various neoplasms including endocrine tumours. Using immunohistochemistry, the expression of SST₁, SST_2A, SST_2B, SST₃, SST₄, and SST₅ was studied in tissue microarrays (TMAs), using a series of 90 human pituitary adenomas producing growth hormone and/or prolactin, including 30 of each somatotroph, lactotroph, and mixed somatotroph/lactotroph adenoma type.

Methods: For immunohistochemistry, the standard avidin biotin complex method enhanced by tyramide was used, using polyclonal antisera for all SST types. A four point scoring system was used to assess the membranous immunopositivity.

Results: All SST types were positive in all tumour types, showing varying immunoreactivity scores. SST₅ and SST_2A were the predominant receptors, showing strong expression in high frequency in all three adenoma types. Strong expression of SST₁ was higher in lactotroph adenomas than in other tumour types.

Conclusions: The immunohistochemical results of SST expression are in agreement with most findings of previous molecular studies. The fact that SST_2A expression is predominant suggests that pharmaceutical octapeptide somatostatin analogues may act through this receptor, while the role of SST_2B may be merely synergistic.

Abbreviations: GH, growth hormone; PRL, prolactin, SST, somatostatin receptors; TMA, tissue microarray

Keywords: adenomas; immunohistochemistry; pituitary; receptors; somatostatin

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Fusco, A., Gunz, G., Jaquet, P., Dufour, H., Germanetti, A. L., Culler, M. D, Barlier, A., Saveanu, A. (2008). Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol 158: 595-603 [Abstract] [Full Text]  
• Plockinger, U., Albrecht, S., Mawrin, C., Saeger, W., Buchfelder, M., Petersenn, S., Schulz, S. (2008). Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone-Secreting Adenomas. J. Clin. Endocrinol. Metab. 93: 1203-1210 [Abstract] [Full Text]  
• Ben-Shlomo, A., Pichurin, O., Barshop, N. J., Wawrowsky, K. A., Taylor, J., Culler, M. D., Chesnokova, V., Liu, N.-A., Melmed, S. (2007). Selective Regulation of Somatostatin Receptor Subtype Signaling: Evidence for Constitutive Receptor Activation. Mol. Endocrinol. 21: 2565-2578 [Abstract] [Full Text]  
• Batista, D. L., Zhang, X., Gejman, R., Ansell, P. J., Zhou, Y., Johnson, S. A., Swearingen, B., Hedley-Whyte, E. T., Stratakis, C. A., Klibanski, A. (2006). The Effects of SOM230 on Cell Proliferation and Adrenocorticotropin Secretion in Human Corticotroph Pituitary Adenomas. J. Clin. Endocrinol. Metab. 91: 4482-4488 [Abstract] [Full Text]